Cushman & Wakefield and JLL represented the tenant in the long-term lease transaction
SEATTLE, Wash., August 24, 2022 – Cushman & Wakefield and JLL today jointly announced that the firms have represented Sonoma Biotherapeutics, Inc. in a long-term lease agreement to develop an approximately 83,000-square-foot Research and Development (R&D) and Manufacturing Center in Seattle, Washington.
Sonoma Bio is a clinical-stage biotechnology company focused on developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases. The state-of-the-art facility will support the R&D and manufacturing of Sonoma Bio’s pipeline of gene-modified Treg therapies for autoimmune and inflammatory diseases at scale.
Managing Director Steve Lico of Cushman & Wakefield’s Palo Alto office and Managing Director Kris Richey Curtis of JLL’s Seattle office represented Sonoma Bio in the transaction. Lico and Richey Curtis have partnered to represent Sonoma Bio since the biotech company’s inception in 2019.
“As we continue to watch the Seattle biotech ecosystem expand and evolve, we are excited to support Sonoma Bio’s significant growth in Seattle,” said Richey Curtis.
Sonoma Bio’s new R&D and Manufacturing Center will include the development and use of cutting-edge technologies and capabilities, from cell selection and genetic modification to intelligent manufacturing automation and information technology systems. The integration of this infrastructure and scientific expertise will enable Sonoma Bio to move efficiently from molecular target identification to in-house full-scale production for multiple products and indications in Phase 2 clinical trials and beyond.
The center will be located at 501 Elliott Avenue West, a property owned by Office Properties Income Trust and being redeveloped by The RMR Group into Unison Elliott Bay. Sonoma Bio will serve as the anchor tenant kicking off leasing activity at the three-building project. Tim Jones and Joe Gowan of JLL serve as the project’s leasing team and represented RMR in the lease.
“Seattle has an established legacy of delivering many firsts in the cell therapy field for cancer and we are building upon those insights to advance our pipeline of engineered Treg therapies for autoimmune and inflammatory diseases,” said Jeff Bluestone, Ph.D., Co-Founder, and CEO of Sonoma Bio. “This Center will create highly-skilled scientific, engineering and manufacturing jobs in the Seattle area, taking advantage of the deep local capabilities and expertise. As we move into the next phase of growth at Sonoma Bio, we want to unite talent across the thriving life science communities of Seattle and San Francisco.”
About Cushman & Wakefield
Cushman & Wakefield (NYSE: CWK) is a leading global real estate services firm that delivers exceptional value for real estate occupiers and owners. Cushman & Wakefield is among the largest real estate services firms with approximately 50,000 employees in over 400 offices and approximately 60 countries. In 2021, the firm had revenue of $9.4 billion across core services of property, facilities and project management, leasing, capital markets, and valuation and other services. To learn more, visit www.cushmanwakefield.com or follow @CushWake on Twitter.
About JLL
JLL (NYSE: JLL) is a leading professional services firm that specializes in real estate and investment management. JLL shapes the future of real estate for a better world by using the most advanced technology to create rewarding opportunities, amazing spaces, and sustainable real estate solutions for our clients, our people, and our communities. JLL is a Fortune 500 company with annual revenue of $19.4 billion, operations in over 80 countries, and a global workforce of more than 100,000 as of March 31, 2022. JLL is the brand name, and a registered trademark, of Jones Lang LaSalle Incorporated. For further information, visit ir.jll.com.
About Sonoma Biotherapeutics
Sonoma Biotherapeutics is a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies to treat serious autoimmune and inflammatory diseases by restoring balance to the immune system. Founded by pioneers in Treg biology and cell therapy, the company is employing proprietary platform technologies and approaches to develop a new generation of targeted and durable Treg cell therapies designed to cure autoimmune and inflammatory diseases. Sonoma Biotherapeutics is based in South San Francisco and Seattle. For more information visit sonomabio.com and follow on Twitter and LinkedIn.
The full content of this article is only available to paid subscribers. If you are an active subscriber, please log in. To subscribe, please click here: SUBSCRIBE
